Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
- PMID: 30487695
- PMCID: PMC6250924
- DOI: 10.3748/wjg.v24.i43.4846
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
Abstract
This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further research in this understudied malignancy. Pancreatic adenocarcinoma is a lethal condition with a rising incidence, predicted to become the second leading cause of cancer death in some regions. It often presents at an advanced stage, which contributes to poor five-year survival rates of 2%-9%, ranking firmly last amongst all cancer sites in terms of prognostic outcomes for patients. Better understanding of the risk factors and symptoms associated with this disease is essential to inform both health professionals and the general population of potential preventive and/or early detection measures. The identification of high-risk patients who could benefit from screening to detect pre-malignant conditions such as pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms and mucinous cystic neoplasms is urgently required, however an acceptable screening test has yet to be identified. The management of pancreatic adenocarcinoma is evolving, with the introduction of new surgical techniques and medical therapies such as laparoscopic techniques and neo-adjuvant chemoradiotherapy, however this has only led to modest improvements in outcomes. The identification of novel biomarkers is desirable to move towards a precision medicine era, where pancreatic cancer therapy can be tailored to the individual patient, while unnecessary treatments that have negative consequences on quality of life could be prevented for others. Research efforts must also focus on the development of new agents and delivery systems. Overall, considerable progress is required to reduce the burden associated with pancreatic cancer. Recent, renewed efforts to fund large consortia and research into pancreatic adenocarcinoma are welcomed, but further streams will be necessary to facilitate the momentum needed to bring breakthroughs seen for other cancer sites.
Keywords: Pancreatic adenocarcinoma; Pancreatic cancer; Pancreatic cancer risk factors; Pancreatic cancer treatment.
Conflict of interest statement
Conflict-of-interest statement: All the authors of this manuscript confirm there is no conflict of interest.
Figures
Similar articles
-
Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.J Gastrointest Cancer. 2020 Sep;51(3):836-843. doi: 10.1007/s12029-019-00303-z. J Gastrointest Cancer. 2020. PMID: 31605289
-
Familial Pancreatic Cancer.Oncol Res Treat. 2018;41(10):611-618. doi: 10.1159/000493473. Epub 2018 Sep 28. Oncol Res Treat. 2018. PMID: 30269130 Review.
-
Surveillance of patients with intraductal papillary mucinous neoplasm with and without pancreatectomy with special reference to the incidence of concomitant pancreatic ductal adenocarcinoma.Surgery. 2018 Feb;163(2):291-299. doi: 10.1016/j.surg.2017.09.040. Epub 2017 Dec 6. Surgery. 2018. PMID: 29221879
-
[Cystic pancreatic tumors: diagnostics and new biomarkers].Chirurg. 2017 Nov;88(11):905-912. doi: 10.1007/s00104-017-0493-1. Chirurg. 2017. PMID: 28831506 Review. German.
-
Update on the management of pancreatic cancer: surgery is not enough.World J Gastroenterol. 2015 Mar 21;21(11):3157-65. doi: 10.3748/wjg.v21.i11.3157. World J Gastroenterol. 2015. PMID: 25805920 Free PMC article. Review.
Cited by
-
Unveiling the role of interleukin-6 in pancreatic cancer occurrence and progression.Front Endocrinol (Lausanne). 2024 May 17;15:1408312. doi: 10.3389/fendo.2024.1408312. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38828409 Free PMC article. Review.
-
Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression.Nat Commun. 2024 May 30;15(1):4099. doi: 10.1038/s41467-024-48441-8. Nat Commun. 2024. PMID: 38816352 Free PMC article.
-
radioGWAS links radiome to genome to discover driver genes with somatic mutations for heterogeneous tumor image phenotype in pancreatic cancer.Sci Rep. 2024 May 29;14(1):12316. doi: 10.1038/s41598-024-62741-5. Sci Rep. 2024. PMID: 38811597 Free PMC article.
-
Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer.Yonsei Med J. 2024 Jun;65(6):324-331. doi: 10.3349/ymj.2023.0399. Yonsei Med J. 2024. PMID: 38804026 Free PMC article.
-
Network dynamics and therapeutic aspects of mRNA and protein markers with the recurrence sites of pancreatic cancer.Heliyon. 2024 May 17;10(10):e31437. doi: 10.1016/j.heliyon.2024.e31437. eCollection 2024 May 30. Heliyon. 2024. PMID: 38803850 Free PMC article.
References
-
- International Agency for Research on Cancer, World Health Organization. Global Cancer Observatory 2018; Available from: URL: http://gco.iarc.fr/
-
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical